SE452249B - Synergistisk och stabil farmaceutisk blandning innefattande natriumkromoglykat i kombination med en beta 2-selektiv bronkodilator - Google Patents

Synergistisk och stabil farmaceutisk blandning innefattande natriumkromoglykat i kombination med en beta 2-selektiv bronkodilator

Info

Publication number: SE452249B
Authority: SE; Sweden
Prior art keywords: weight; butylamino; active ingredient; synergistic; hydroxy
Prior art date: 1980-04-30

Application number

SE8102732A

Other languages

English (en)

Swedish (sv)

Other versions

SE8102732L (sv

Inventor

H Cairns

P M Greenhalgh

B Howlett

Original Assignee

Fisons Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-04-30

Filing date

1981-04-29

Publication date

1987-11-23

1981-04-29 Application filed by Fisons Ltd filed Critical Fisons Ltd

1981-10-31 Publication of SE8102732L publication Critical patent/SE8102732L/

1987-11-23 Publication of SE452249B publication Critical patent/SE452249B/sv

Links

239000000203 mixture Substances 0.000 title claims description 55
230000002195 synergetic effect Effects 0.000 title claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title 1
229910052708 sodium Inorganic materials 0.000 title 1
239000011734 sodium Substances 0.000 title 1
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 32
239000004480 active ingredient Substances 0.000 claims description 21
150000001875 compounds Chemical class 0.000 claims description 16
-1 3,5-dihydroxyphenyl Chemical group 0.000 claims description 11
239000000443 aerosol Substances 0.000 claims description 7
239000007787 solid Substances 0.000 claims description 7
239000004094 surface-active agent Substances 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims description 3
229960000278 theophylline Drugs 0.000 claims description 3
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 2
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims 1
239000002245 particle Substances 0.000 description 30
229960000265 cromoglicic acid Drugs 0.000 description 27
239000003380 propellant Substances 0.000 description 14
238000002360 preparation method Methods 0.000 description 13
239000000463 material Substances 0.000 description 12
239000000843 powder Substances 0.000 description 10
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 9
239000008101 lactose Substances 0.000 description 9
239000007788 liquid Substances 0.000 description 9
239000003814 drug Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000008187 granular material Substances 0.000 description 8
239000008188 pellet Substances 0.000 description 8
125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
206010006482 Bronchospasm Diseases 0.000 description 7
KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 7
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 7
239000013543 active substance Substances 0.000 description 7
229940124630 bronchodilator Drugs 0.000 description 7
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 7
235000019404 dichlorodifluoromethane Nutrition 0.000 description 7
229940079593 drug Drugs 0.000 description 7
239000004338 Dichlorodifluoromethane Substances 0.000 description 6
239000004147 Sorbitan trioleate Substances 0.000 description 6
239000000427 antigen Substances 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
230000007885 bronchoconstriction Effects 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
235000019337 sorbitan trioleate Nutrition 0.000 description 6
229960000391 sorbitan trioleate Drugs 0.000 description 6
210000003437 trachea Anatomy 0.000 description 6
241000700159 Rattus Species 0.000 description 5
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
230000009471 action Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 5
239000002736 nonionic surfactant Substances 0.000 description 5
JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
CFUSMTBQBWPGOZ-UHFFFAOYSA-N Terbutaline-1-sulfate Chemical compound CC(C)(C)NCC(OS(O)(=O)=O)C1=CC(O)=CC(O)=C1 CFUSMTBQBWPGOZ-UHFFFAOYSA-N 0.000 description 4
239000000168 bronchodilator agent Substances 0.000 description 4
229960001317 isoprenaline Drugs 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 4
229940029284 trichlorofluoromethane Drugs 0.000 description 4
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229930195725 Mannitol Natural products 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
206010070834 Sensitisation Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
150000001335 aliphatic alkanes Chemical class 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
210000002837 heart atrium Anatomy 0.000 description 3
239000000594 mannitol Substances 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
230000008313 sensitization Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000032258 transport Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
241000700199 Cavia porcellus Species 0.000 description 2
101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000002052 anaphylactic effect Effects 0.000 description 2
239000003945 anionic surfactant Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
QPAXMPYBNSHKAK-UHFFFAOYSA-N chloro(difluoro)methane Chemical compound F[C](F)Cl QPAXMPYBNSHKAK-UHFFFAOYSA-N 0.000 description 2
239000011362 coarse particle Substances 0.000 description 2
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000446 fuel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
238000000034 method Methods 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000011514 reflex Effects 0.000 description 2
230000002040 relaxant effect Effects 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
125000003944 tolyl group Chemical group 0.000 description 2
CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
AJDIZQLSFPQPEY-UHFFFAOYSA-N 1,1,2-Trichlorotrifluoroethane Chemical compound FC(F)(Cl)C(F)(Cl)Cl AJDIZQLSFPQPEY-UHFFFAOYSA-N 0.000 description 1
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
206010006440 Bronchial obstruction Diseases 0.000 description 1
BGRJBOIFHJBRNU-UHFFFAOYSA-N CC(C)(C)NCC(C(C=CC1)=CC1(O)O)OS(O)(=O)=O Chemical compound CC(C)(C)NCC(C(C=CC1)=CC1(O)O)OS(O)(=O)=O BGRJBOIFHJBRNU-UHFFFAOYSA-N 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108010026206 Conalbumin Proteins 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
239000004386 Erythritol Substances 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
206010028748 Nasal obstruction Diseases 0.000 description 1
241000336691 Notolopas brasiliensis Species 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
208000007027 Oral Candidiasis Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
241000287181 Sturnus vulgaris Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000287411 Turdidae Species 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
201000009961 allergic asthma Diseases 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
235000020661 alpha-linolenic acid Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
238000010171 animal model Methods 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
238000010009 beating Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000001273 butane Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
239000001527 calcium lactate Substances 0.000 description 1
229960002401 calcium lactate Drugs 0.000 description 1
235000011086 calcium lactate Nutrition 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000000991 chicken egg Anatomy 0.000 description 1
AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
229940099364 dichlorofluoromethane Drugs 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
235000014103 egg white Nutrition 0.000 description 1
230000005611 electricity Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
229940009714 erythritol Drugs 0.000 description 1
235000019414 erythritol Nutrition 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
238000005243 fluidization Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
230000036541 health Effects 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
239000012212 insulator Substances 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229960004488 linolenic acid Drugs 0.000 description 1
KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
230000004199 lung function Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000002483 medication Methods 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
LMOINURANNBYCM-UHFFFAOYSA-N metaproterenol Chemical compound CC(C)NCC(O)C1=CC(O)=CC(O)=C1 LMOINURANNBYCM-UHFFFAOYSA-N 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000000754 myometrium Anatomy 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical class CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
229960002657 orciprenaline Drugs 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
239000001433 sodium tartrate Substances 0.000 description 1
229960002167 sodium tartrate Drugs 0.000 description 1
235000011004 sodium tartrates Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000004544 sputter deposition Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SE8102732A 1980-04-30 1981-04-29 Synergistisk och stabil farmaceutisk blandning innefattande natriumkromoglykat i kombination med en beta 2-selektiv bronkodilator SE452249B (sv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB8014197		1980-04-30
GB8105306		1981-02-19

Publications (2)

Publication Number	Publication Date
SE8102732L SE8102732L (sv)	1981-10-31
SE452249B true SE452249B (sv)	1987-11-23

Family

ID=26275361

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8102732A SE452249B (sv)	1980-04-30	1981-04-29	Synergistisk och stabil farmaceutisk blandning innefattande natriumkromoglykat i kombination med en beta 2-selektiv bronkodilator

Country Status (15)

Country	Link
US (1)	US4409237A (fr)
AU (1)	AU529935B2 (fr)
CA (1)	CA1178891A (fr)
CH (1)	CH653330A5 (fr)
CY (1)	CY1333A (fr)
DE (1)	DE3117327C3 (fr)
FR (1)	FR2481601A1 (fr)
GB (1)	GB2077100B (fr)
HK (1)	HK43186A (fr)
IE (1)	IE51150B1 (fr)
IL (1)	IL62744A (fr)
LU (1)	LU83328A1 (fr)
NL (1)	NL191172C (fr)
NZ (1)	NZ196950A (fr)
SE (1)	SE452249B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4917897A (en) *	1982-01-22	1990-04-17	Fisons Plc	Pharmaceutical compositions
SE8303401D0 (sv) *	1983-06-15	1983-06-15	Pharmacia Ab	Beredning och dess anvendning
GB9001635D0 (en) *	1990-01-24	1990-03-21	Ganderton David	Aerosol carriers
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
GB9317752D0 (en) *	1993-08-26	1993-10-13	Fisons Plc	New pharmaceutical use
DE4425255A1 (de)	1994-07-16	1996-01-18	Asta Medica Ag	Formulierung zur inhalativen Applikation
AU749697B2 (en) *	1998-08-04	2002-07-04	Jagotec Ag	Medicinal aerosol formulations
WO2001077328A1 (fr) *	2000-04-06	2001-10-18	Franco Wayne P	Methodes d'utilisation de facteurs de croissance pour traiter une cardiopathie
US20030026859A1 (en) *	2000-08-03	2003-02-06	Adolfo Goren	Antiviral composition derived from Allium cepa and therapeutic use thereof
US6596284B1 (en)	2002-04-30	2003-07-22	Thomas E. Fleming	Treating eczema with a combination of isotonic saline ocean® and nasal mast cell stabilizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1792807U (de)	1958-09-12	1959-07-30	Goetzewerke	Gleitringdichtung.
CH379526A (it) *	1958-12-29	1964-07-15	Guidotti & C Sa Lab	Procedimento per ottenere composti derivati dal 5-idrossi-8-metossi-2-metil-4',5'-furo-6,7-cromone
GB1144905A (en) *	1965-03-25	1969-03-12	Fisons Pharmaceuticals Ltd	Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
GB1204121A (en) *	1966-09-19	1970-09-03	Fisons Pharmaceuticals Ltd	Novel bis-chromonyl compounds, their preparation and use
GB1242211A (en) *	1967-08-08	1971-08-11	Fisons Pharmaceuticals Ltd	Pharmaceutical composition
FR2190410A1 (en) *	1972-06-29	1974-02-01	Aries Robert	7-(Aminoalkyl)theophylline salts - with a bis(2-carboxychromon-5-yloxy)alkane with prolonged prophylactic action against bronchospasm
FR2196795A1 (en) *	1972-08-25	1974-03-22	Aries Robert	Amine salts of bis(carboxychromones) - useful for treatment of dyspnoea and bronchoconstriction
FI770215A7 (fr) *	1976-01-30	1977-07-31	Fisons Ltd

1981
- 1981-04-08 GB GB8110995A patent/GB2077100B/en not_active Expired
- 1981-04-08 CY CY133381A patent/CY1333A/en unknown
- 1981-04-21 US US06/256,021 patent/US4409237A/en not_active Expired - Lifetime
- 1981-04-27 AU AU69856/81A patent/AU529935B2/en not_active Expired
- 1981-04-27 NL NL8102054A patent/NL191172C/xx not_active IP Right Cessation
- 1981-04-28 IL IL62744A patent/IL62744A/xx not_active IP Right Cessation
- 1981-04-28 NZ NZ196950A patent/NZ196950A/en unknown
- 1981-04-29 CA CA000376535A patent/CA1178891A/fr not_active Expired
- 1981-04-29 FR FR8108561A patent/FR2481601A1/fr active Granted
- 1981-04-29 CH CH2795/81A patent/CH653330A5/fr not_active IP Right Cessation
- 1981-04-29 LU LU83328A patent/LU83328A1/fr unknown
- 1981-04-29 SE SE8102732A patent/SE452249B/sv not_active Application Discontinuation
- 1981-04-29 IE IE951/81A patent/IE51150B1/en not_active IP Right Cessation
- 1981-04-30 DE DE3117327A patent/DE3117327C3/de not_active Expired - Lifetime
1986
- 1986-06-09 HK HK431/86A patent/HK43186A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE3117327A1 (de)	1982-04-01
IL62744A0 (en)	1981-06-29
US4409237A (en)	1983-10-11
SE8102732L (sv)	1981-10-31
AU6985681A (en)	1981-11-05
IE51150B1 (en)	1986-10-15
GB2077100A (en)	1981-12-16
AU529935B2 (en)	1983-06-23
DE3117327C2 (fr)	1992-05-27
NL8102054A (nl)	1981-11-16
NZ196950A (en)	1985-07-12
FR2481601B1 (fr)	1984-08-10
IE810951L (en)	1981-10-30
HK43186A (en)	1986-06-20
NL191172C (nl)	1995-03-01
FR2481601A1 (fr)	1981-11-06
NL191172B (nl)	1994-10-03
DE3117327C3 (de)	1996-11-21
IL62744A (en)	1985-10-31
GB2077100B (en)	1985-04-24
LU83328A1 (fr)	1981-07-24
CY1333A (en)	1986-10-24
CA1178891A (fr)	1984-12-04
CH653330A5 (fr)	1985-12-31

Legal Events

Date

Code

Title

Description

1996-01-08

NAV

Patent application has lapsed

Ref document number: 8102732-8

Format of ref document f/p: F

Publication	Publication Date	Title
AU714303B2 (en)	1999-12-23	Formulation for intranasal administration
EP0309519B1 (fr)	1992-07-08	Compositions pharmaceutiques contenant de la pentamidine
US5204113A (en)	1993-04-20	Pharmaceutical compositions containing pentamidine
RU2006112589A (ru)	2007-11-10	Фармацевтические композиции для лечения преждевременной эякуляции при помощи легочной ингаляции
PT1283036E (pt)	2008-03-06	Inalador de pó seco de dose múltipla com um reservatório de pó
SE452249B (sv)	1987-11-23	Synergistisk och stabil farmaceutisk blandning innefattande natriumkromoglykat i kombination med en beta 2-selektiv bronkodilator
US8765153B2 (en)	2014-07-01	Levalbuterol salt
WO1990011754A1 (fr)	1990-10-18	Fongicides au pyrrol en aerosol
MXPA06013040A (es)	2007-02-12	El tratamiento del asma infantil.
EP0285246B1 (fr)	1992-01-02	Dérivé de dioxo-4,6 4-H-pyrano[3,2-g]quinoléine-2,8-dicarboxylate de calcium, procédé pour sa préparation et compositions le contenant
WO2004041263A1 (fr)	2004-05-21	Nouvelles compositions pharmaceutiques contenant de l'ambroxol et de l'iodure d'isopropamide
HRP20010403A2 (en)	2002-06-30	Composition containing an analgesic and a xanthine or a xanthine derivative
JP2006509802A5 (fr)	2006-11-24
McDonald et al.	1962	The effect of certain psychotropic drugs on the urinary excretion of 3-methoxy-4-hydroxymandelic acid in man
US2916417A (en)	1959-12-08	Article of manufacture
JPH0149692B2 (fr)	1989-10-25
Frischknecht et al.	1978	Actions of hallucinogens on ants (Formica pratensis)—II. Effects of amphetamine, LSD and delta-9-tetrahydrocannabinol
Abarzua et al.	1979	Drugs Other than Corticosteroids for the Treatment of Asthma
EP0266640A2 (fr)	1988-05-11	Complexe pharmaceutique contenant de la nifédipine
O'Hara et al.	1989	Therapy of childhood asthma
NL9401594A (nl)	1995-01-02	Farmaceutisch mengsel dat 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol bevat in combinatie met een bronchiën-verwijdend middel, alsmede farmaceutisch preparaat voor de behandeling van allergische longaandoeningen.
NL9401593A (nl)	1995-01-02	Farmaceutisch mengsel dat 1,3-bis(2-carboxychromon-5-yloxy)propan-2-ol bevat in combinatie met een bronchiën-verwijdend middel, alsmede farmaceutisch preparaat voor de behandeling van allergische longaandoeningen.